Bearish flow noted in GSK (GSK) Pharma with 6,103 puts trading, or 5x expected. Most active are 3/14 weekly 39.5 puts and Mar-25 41.5 calls, with total volume in those strikes near 5,500 contracts.

The market was pleased with the recent earnings report from GSK plc (LON:GSK), despite the profit numbers being soft. However, we think the company is showing some signs that things are more ...

LONDON, - British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. president's ...

GSK (GSK) plc announced that it has completed the acquisition of IDRx, Inc., a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the ...

Now, GSK is ready to play catch-up after nabbing its own FDA approval. The FDA approved the British drugmaker's Penmenvy vaccine to protect people ages 10 to 25 against meningococcal serogroups A ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its ...

Tony Wood, Chief Scientific Officer, GSK, said: "We are excited about the opportunities ahead to help improve meningococcal vaccination coverage in the United States, especially for IMD caused by ...

GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the ...

US regulators have approved a new meningitis vaccine developed by GSK, sparking cautious optimism for the sector in the wake of Donald Trump's election for a second term as President. The Food ...

CDC vaccine advisors are set to discuss recommendations for the vaccine on Feb. 26. The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 ...

The shares of GlaxoSmithKline Pharmaceuticals Ltd (GSK Pharma) jumped over 15 percent to trade at Rs 2,684 apiece on February 18, extending gains for the second straight session after releasing ...

The quarter saw strong performance across key product portfolios. Flagship brands within the general medicines portfolio, including Augmentin, Ceftum, and T-Bact, strengthened their market ...